On the Radar: Five high-value biotech stocks

Our new On the Radar report returns with fresh insights from Simos Simeonidis, PhD, Rodman & Renshaw's senior biotech analyst, who highlights biotech stocks which he believes will be good value

STALLERGENES And ActoGenix To Develop An Innovative New Class Of Oral Allergy Treatments

STALLERGENES exercised option to pursue the exclusive development of application of ActoGeniX's technology for targeted delivery of allergen-based treatments ANTONY, France and GHENT, Belgium,...

Ablynx amps up expectations for rare disease drug; Boehringer nears EU nod for IPF contender;

@FierceBiotech: EuroBiotech Report: U.K. starts ambitious drug dev review, Onxeo to raise €41.6M, Galapagos mulls Nasdaq listing. More | Follow @FierceBiotech @JohnCFierce: 5 of the top 10...

AstraZeneca earmarks $200M to support its burgeoning biologics pipeline

Thanks in part to its all-hands approach to immuno-oncology, AstraZeneca's pipeline is now nearly 50% biologics, leading the company to lay out $200 million to build the capacity it will need to follow through on those in-development projects.

AstraZeneca Announces Plans to Expand its Frederick, Maryland Biologics Manufacturing Center

FREDERICK, Md.--AstraZeneca today announced plans to expand its biologics manufacturing center in Frederick, Md. The more than $200 million project will increase production capacity at the facility...

Biotech Neothetics pulls off a $65M IPO and promptly takes a tumble

San Diego's Neothetics, developer of a fat-busting treatment, came through on its plans to raise $65 million in an IPO, but, in keeping with a growing trend in biotech, watched its shares slide shortly after its debut.

Neothetics Prices Initial Public Offering

SAN DIEGO -- Neothetics, Inc. (NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced the pricing of its initial public offering of...

Beware sketchy biotechs with big plans for Ebola, SEC says

The SEC has suspended the trading of a few microcap companies touting unverified Ebola treatments and tests, warning investors of penny stock peddlers looking to cash in on the West African outbreak that has killed thousands.

SEC Suspends Trading in Companies Touting Operations Related to Prevention or Treatment of Ebola

Agency Issues Investor Alert Warning of Fraud Risks in Thinly-Traded Stocks of Companies Linking Future Business Prospects to Ebola Outbreak Washington D.C., Nov. 20, 2014 — The Securities and...

Scholar Rock Appoints Gregory J. Carven, PhD, as Vice President of Antibody Discovery and Protein Sciences

Discovery Leader with Accomplished Track Record of Discovering Breakthrough Medicines from Invention to IND Filing CAMBRIDGE, Mass., Nov. 20, 2014 – Scholar Rock, a biotechnology company...